Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Preferred Shares (2016)

Arrowhead Pharmaceuticals (ARWR) has disclosed Preferred Shares for 5 consecutive years, with $16.0 as the latest value for Q3 2016.

  • For the quarter ending Q3 2016, Preferred Shares changed 0.0% year-over-year to $16.0, compared with a TTM value of $16.0 through Sep 2016, changed 0.0%, and an annual FY2016 reading of $16.0, changed 0.0% over the prior year.
  • Preferred Shares was $16.0 for Q3 2016 at Arrowhead Pharmaceuticals, roughly flat from $16.0 in the prior quarter.
  • Across five years, Preferred Shares topped out at $51.0 in Q4 2013 and bottomed at $10.0 in Q2 2013.
  • Average Preferred Shares over 4 years is $18.64, with a median of $16.0 recorded in 2015.
  • Peak annual rise in Preferred Shares hit 110.0% in 2014, while the deepest fall reached 64.71% in 2014.
  • Year by year, Preferred Shares stood at $51.0 in 2013, then tumbled by 64.71% to $18.0 in 2014, then fell by 11.11% to $16.0 in 2015, then changed by 0.0% to $16.0 in 2016.
  • Business Quant data shows Preferred Shares for ARWR at $16.0 in Q3 2016, $16.0 in Q2 2016, and $16.0 in Q1 2016.